Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Immune Landscape and Therapeutic Strategies: New Insights into PD-L1 in Tumors

Recent progress in the combination treatment of radiotherapy and PD-1/PD-L1 signaling blockade immunotherapy

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Generation, secretion and degradation of cancer immunotherapy target PD-L1

PD-1 regulation in immune homeostasis and immunotherapy

Research progress of tumor targeted drug delivery based on PD-1/PD-L1

PD-1/PD-L1 pathway: current researches in cancer.

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders

Post-translational Modification of PD-1: Potential Pathways for Cancer Immunotherapy

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

Addressing the Challenges of PD-1 Targeted Immunotherapy in Cancer Treatment

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway